Pirtobrutinib + Placebo

Phase 1/2Recruiting

1 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Immune Thrombocytopenia (ITP)

Conditions

Immune Thrombocytopenia (ITP)

Trial Timeline

Jul 30, 2025 → Feb 1, 2027

NCT ID

NCT06721013

About Pirtobrutinib + Placebo

Pirtobrutinib + Placebo is a phase 1/2 stage product being developed by Eli Lilly for Immune Thrombocytopenia (ITP). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06721013. Target conditions include Immune Thrombocytopenia (ITP).

What happened to similar drugs?

7 of 20 similar drugs in Immune Thrombocytopenia (ITP) were approved

Approved (7) Terminated (2) Active (13)

✅Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved

✅IgPro10CSLApproved

✅Subcutaneous Immune Globulin (Human) (Hizentra)CSLApproved

✅Methylprednisolone + PrednisoloneBiogenApproved

✅Flebogamma 5% DIFGrifolsApproved

✅Asceniv™ADMA BiologicsApproved

✅BivigamADMA BiologicsApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06721013	Phase 1/2	Recruiting	Jul 30, 2025	Feb 1, 2027	Immune Thrombocytopenia (ITP)

Competing Products

20 competing products in Immune Thrombocytopenia (ITP)

See all competitors

Product	Company	Stage	Hype Score
Anti-(integrin beta-3) human monoclonal antibody	Rallybio	Phase 2	17
Satralizumab	Chugai Pharmaceutical	Phase 3	47
Placebo + Lusutrombopag	Shionogi	Phase 2	27
Lusutrombopag	Shionogi	Phase 2	27
Romiplostim	Kyowa Kirin	Phase 1/2	32
AMG 531	Kyowa Kirin	Phase 2/3	38
Romiplostim + Placebo	Kyowa Kirin	Phase 3	40
Romiplostim (AMG-531)	Kyowa Kirin	Phase 2	35
Romiplostim and danazol	Kyowa Kirin	Phase 2	31
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 1	29
SHR0302 quick release tablets + SHR0302 sustained-release tablets	Jiangsu Hengrui Medicine	Phase 1	29
Hetrombopag + Placebo	Jiangsu Hengrui Medicine	Phase 3	40
HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu Hengrui Medicine	Phase 1	29
HR19042 Capsules	Jiangsu Hengrui Medicine	Phase 2	35
Herombopag	Jiangsu Hengrui Medicine	Phase 3	36
Zostavax®	Merck	Pre-clinical	18
Raltegravir + Atazanavir	Merck	Pre-clinical	26
Zostavax	Merck	Pre-clinical	26
MK-8723 + Matching Placebo	Merck	Phase 1	29
Eltrombopag (Revolade®) + standard therapy (without eltrombopag): HD-DXM	Novartis	Phase 2	35